Core Insights - Merck has received FDA approval for KEYTRUDA QLEX, a new formulation for subcutaneous administration in adults for most solid tumor indications of KEYTRUDA [1] Company Summary - KEYTRUDA QLEX combines pembrolizumab with berahyaluronidase alfa-pmph, a variant of human hyaluronidase developed by Alteogen Inc [1] - The approval expands the administration options for KEYTRUDA, which is a significant product for Merck in oncology [1]